Shares of Fulgent Genetics Inc. (FLGT) surged 10.59% in pre-market trading on Friday, following the company's release of better-than-expected second-quarter 2025 financial results and an upward revision of its full-year guidance.
The genetic testing solutions provider reported adjusted earnings per share of $0.07 for Q2, significantly beating analyst estimates of a $0.18 loss per share. Revenue for the quarter came in at $81.803 million, surpassing the consensus estimate of $76.205 million and representing a 15.17% increase from the same period last year. The company's core revenue, a key metric for its operations, reached $81.7 million for the quarter.
Adding to the positive sentiment, Fulgent Genetics raised its 2025 core revenue guidance to $320 million, signaling strong confidence in its growth trajectory. However, the company also provided an outlook for a full-year non-GAAP loss per share of about $0.35. Despite this, investors appear to be focusing on the revenue growth and the company's ability to outperform expectations in a challenging market environment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.